Online inquiry

IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1882MR)

This product GTTS-WQ1882MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets CTLA4 gene. The antibody can be applied in Non-Small Cell Lung Cancers (NSCLC) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_001037631.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 1493
UniProt ID P16410
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CTLA4, AGEN1884(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ1882MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5666MR IVTScrip™ mRNA-Anti-GPNMB, CDX-011(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA CDX-011
GTTS-WQ14756MR IVTScrip™ mRNA-Anti-TNFRSF8, SGN-35(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA SGN-35
GTTS-WQ11315MR IVTScrip™ mRNA-Anti-F, MEDI-524(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MEDI-524
GTTS-WQ5709MR IVTScrip™ mRNA-Anti-CD3E&CEACAM5, CEA TCB(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA CEA TCB
GTTS-WQ195MR IVTScrip™ mRNA-Anti-VEGFA, 12-IgG1(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA 12-IgG1
GTTS-WQ10483MR IVTScrip™ mRNA-Anti-CGRP, LY-2951742(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA LY-2951742
GTTS-WQ12862MR IVTScrip™ mRNA-Anti-TLR2, OPN-305(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA OPN-305
GTTS-WQ11987MR IVTScrip™ mRNA-Anti-ERBB3, MM-121(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MM-121
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW